News
Vaxxas has landed $90 million in debt and equity funding to develop technology that could replace the flu jab and other ...
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results